Teva Targets $113 Billion In Branded Sales With Dozens Of Pending Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
The Israeli drug maker reports sales rose by 25 percent in 2009, and takes aim at a plethora of generic opportunities
You may also be interested in...
Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug
In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.
Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug
In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.
Teva's Laquinimod Meets Primary Endpoint In First Phase III Study
Favorable safety profile may differentiate Teva's laquinimod from competing oral multiple sclerosis therapies.